Elite Pharmaceuticals (ELTP) AI Stock Analysis

• Market Cap: $546.14M
• Dividend Yield: N/A
• Average Volume (3M): 1.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: 48.42%
• EPS Growth: -120.20%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.02
• Shares Outstanding: 1,070,863,200
• 10 Day Avg. Volume: 776,247
• 30 Day Avg. Volume: 1,690,751
• PEG Ratio: -1.74
• Price to Book (P/B): 10.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 115.52
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 1.94
• Enterprise Value/Gross Profit: 14.12
• Enterprise Value/Ebitda: -275.77
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: $0.50 ▼(-1.96%Downside)

The overall stock score reflects strong revenue growth and a healthy balance sheet, but is tempered by weak technical indicators and valuation concerns due to ongoing losses. The positive insights from the earnings call, including new product success and improved cash flow, help to offset some of these risks.

Elite Pharmaceuticals Business Overview & Revenue Model

Company Description

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

How the Company Makes Money

Elite Pharmaceuticals generates revenue through the development, manufacturing, and sale of generic and branded pharmaceutical products. The company licenses its formulations and technologies to other pharmaceutical companies, earning royalties and milestone payments. Revenue streams include product sales from its own portfolio, as well as licensing fees from partnerships with other pharmaceutical manufacturers. Key partnerships, such as those with larger pharmaceutical companies, enable Elite to expand its market presence and capitalize on its proprietary abuse-deterrent technology, which is a significant factor in driving revenue growth.

Elite Pharmaceuticals Financial Statement Overview

Summary

Elite Pharmaceuticals shows a strong revenue growth trajectory and a robust balance sheet with healthy equity and controlled debt. However, profitability challenges persist due to net losses and fluctuating margins, with inconsistent cash flow performance.

Income Statement

Elite Pharmaceuticals shows a strong revenue growth trajectory, with significant increases in revenue over the past few years. Despite the growth, the company faced a net loss in the latest period, impacting the net profit margin negatively. However, the gross profit margin remains robust, indicating efficient production. The variability in EBITDA margin over the years suggests operational challenges that need addressing.

Balance Sheet

The balance sheet reveals a healthy equity position with a favorable equity ratio, indicating strong financial resilience. The debt-to-equity ratio is manageable, suggesting moderate leverage, which poses less risk to financial stability. Return on equity has fluctuated significantly, reflecting volatility in profitability.

Cash Flow

Cash flow analysis indicates inconsistent free cash flow performance, with recent positive growth but past periods of negative free cash flow. The operating cash flow to net income ratio suggests that cash generation from operations can improve. The company's ability to convert net income into cash remains a challenge, as evidenced by the free cash flow to net income ratio.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	84.04M	56.63M	34.16B	32.26M	25.38M
Gross Profit	40.09M	26.36M	16.59B	14.80M	11.87M
EBITDA	2.84M	2.58M	6.43M	6.27M	5.93M
Net Income	-4.31M	20.11M	4.41B	8.90M	5.09M
Balance Sheet
Total Assets	96.39M	83.65M	40.90M	35.15M	26.19M
Cash, Cash Equivalents and Short-Term Investments	11.32M	7.11M	7.83M	8.54M	3.19M
Total Debt	10.91M	11.74M	3.89M	2.78M	2.38M
Total Liabilities	42.87M	26.07M	11.94M	9.93M	10.04M
Stockholders Equity	53.52M	57.58M	28.96M	25.22M	16.15M
Cash Flow
Free Cash Flow	4.93M	-4.09M	-2.40M	6.01M	2.86M
Operating Cash Flow	7.46M	-3.28M	3.34M	6.51M	3.19M
Investing Cash Flow	-2.40M	-809.65K	-5.74M	-498.57K	-262.78K
Financing Cash Flow	-825.74K	3.39M	1.70M	-667.13K	-869.83K

Elite Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTP, the sentiment is Negative. The current price of 0.51 is below the 20-day moving average (MA) of 0.55, below the 50-day MA of 0.60, and below the 200-day MA of 0.52, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 37.68 is Neutral, neither overbought nor oversold. The STOCH value of 21.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELTP.

Elite Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	85 Outperform	$472.23M	9.73	25.47%	10.13%	-23.37%	-39.03%
AMPH	68 Neutral	$987.56M	7.60	19.90%	―	8.05%	-8.46%
ELTP	61 Neutral	$546.14M	―	-7.77%	―	48.42%	-120.20%
Sector *	61 Neutral	HK$17.40B	5.81	-7.44%	3.53%	11.55%	-28.15%
AVDL	60 Neutral	$1.02B	―	-34.65%	―	252.64%	85.10%
ORGO	58 Neutral	$586.06M	928.57	-4.92%	―	5.35%	-432.51%
AQST	48 Neutral	$381.42M	―	77.48%	―	5.29%	-37.31%

Elite Pharmaceuticals Corporate Events

Elite Pharmaceuticals Reports Strong Fiscal Year Performance

Elite Pharmaceuticals, Inc. reported a significant financial performance for the fiscal year ended March 31, 2025, with consolidated revenues reaching $84.0 million, marking a 48% increase from the previous year. The company’s operating profits rose by 81% to $19.6 million, driven by the successful launch of lisdexamfetamine products and growth in Elite’s existing product lines.

Elite Pharmaceuticals to Announce FY 2025 Results

Elite Pharmaceuticals announced it will release its financial results for the fiscal year ending March 31, 2025, on June 30, 2025. A conference call will be held on July 1, 2025, to discuss these results and provide a business update, indicating a focus on transparency and stakeholder engagement.

Elite Pharmaceuticals Announces Positive Study Results

On June 16, 2025, Elite Pharmaceuticals announced positive results from a pivotal bioequivalence study for an undisclosed generic anticoagulant drug, showing it is equivalent to the branded product. This finding is significant as there is currently no generic version on the market, and the branded product has a patent listed in the Orange Book. Elite plans to file an Abbreviated New Drug Application with the FDA, which could impact the market by introducing a generic alternative, pending successful filing, FDA approval, and patent considerations.